Addendum
Sipavibart (pre exposure prophylaxis of COVID 19) – Addendum to Project A25-28
Report documents
-
Addendum
Sipavibart (pre exposure prophylaxis of COVID 19) – Addendum to Project A25-28
Dossier assessment
Indication:
Pre-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments
Additional information
Federal Joint Committee (G-BA)
07-08-2025 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-84
- Commission
- Commission awarded on 24.06.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-84_en
Connected Projects
-
Dossier assessment
Sipavibart (pre-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed